LAPTM5

Across TCGA pan-cancer cohorts, LAPTM5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LAPTM5 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LAPTM5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAPTM5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where LAPTM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.281	1.000	.001	8	view →
HNSC	DFS	Median	All	0.924	0.640	.016	4	view →
LSCC	OS	Median	III,IV	0.990	0.719	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LAPTM5–LUAD (DFS)

Open the LUAD breakdown →